|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
CA2881057C
(en)
|
2012-08-28 |
2020-10-27 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
JP6466348B2
(ja)
|
2013-02-28 |
2019-02-06 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
|
|
HUE033542T2
(en)
|
2013-04-03 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
|
|
HUE040446T2
(hu)
|
2013-05-17 |
2019-03-28 |
Janssen Sciences Ireland Uc |
Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
|
|
TW202126620A
(zh)
|
2013-05-17 |
2021-07-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
WO2015011281A1
(en)
|
2013-07-25 |
2015-01-29 |
Janssen R&D Ireland |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP6553059B2
(ja)
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
PL3102572T3
(pl)
|
2014-02-06 |
2019-04-30 |
Janssen Sciences Ireland Uc |
Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
|
|
TWI784255B
(zh)
|
2014-12-18 |
2022-11-21 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
EP3312184A4
(en)
*
|
2015-06-16 |
2019-02-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
AR106192A1
(es)
|
2015-09-29 |
2017-12-20 |
Novira Therapeutics Inc |
Formas cristalinas de un agente antiviral contra la hepatitis b
|
|
WO2017059139A1
(en)
|
2015-10-01 |
2017-04-06 |
Olema Pharmaceuticals, Inc. |
TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
|
|
EP3378861B1
(en)
|
2015-11-12 |
2021-08-04 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
DK3386500T3
(da)
|
2015-12-09 |
2022-12-12 |
Univ Illinois |
Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
|
|
WO2017107754A1
(zh)
|
2015-12-22 |
2017-06-29 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物、其制备方法及其在医药上的应用
|
|
CN109362222B
(zh)
*
|
2016-02-05 |
2021-03-19 |
益方生物科技(上海)股份有限公司 |
选择性雌激素受体降解物及其用途
|
|
KR20220071293A
(ko)
|
2016-04-01 |
2022-05-31 |
리커리엄 아이피 홀딩스, 엘엘씨 |
에스트로겐 수용체 조절제
|
|
WO2017181141A2
(en)
|
2016-04-15 |
2017-10-19 |
Novira Therapeutics, Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
TW201803870A
(zh)
|
2016-04-20 |
2018-02-01 |
阿斯特捷利康公司 |
化學化合物
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
CN109661393A
(zh)
*
|
2016-05-08 |
2019-04-19 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109843882A
(zh)
|
2016-06-16 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
CN109311876B
(zh)
*
|
2016-06-16 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
杂芳基雌激素受体调节剂及其用途
|
|
WO2018001232A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
CN109789143A
(zh)
|
2016-07-01 |
2019-05-21 |
G1治疗公司 |
基于嘧啶的抗增殖剂
|
|
US10149839B2
(en)
|
2016-07-25 |
2018-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
JP7050770B2
(ja)
*
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
UA125824C2
(uk)
|
2016-10-24 |
2022-06-15 |
Астразенека Аб |
6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
JP7229162B2
(ja)
|
2017-01-06 |
2023-02-27 |
ジー１ セラピューティクス， インコーポレイテッド |
癌の治療に対する併用療法
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
CR20190379A
(es)
|
2017-01-30 |
2019-10-21 |
Astrazeneca Ab |
Moduladores del receptor de estrógeno
|
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
KR20190117582A
(ko)
|
2017-02-10 |
2019-10-16 |
쥐원 쎄라퓨틱스, 인크. |
벤조티오펜 에스트로겐 수용체 조정제
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
WO2018233591A1
(zh)
*
|
2017-06-20 |
2018-12-27 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
EP3645001B1
(en)
|
2017-06-29 |
2024-07-03 |
G1 Therapeutics, Inc. |
Morphic forms of git38 and methods of manufacture thereof
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
*
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
EP3755683B1
(en)
*
|
2018-02-23 |
2026-07-08 |
Center for Intelligent Research in Crystal Engineering, S.L. |
Cocrystals of ubiquinol and compositions comprising them
|
|
SG11202007097QA
(en)
|
2018-03-14 |
2020-08-28 |
Janssen Sciences Ireland Unlimited Co |
Capsid assembly modulator dosing regimen
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
LT3810283T
(lt)
|
2018-06-21 |
2023-08-25 |
F. Hoffmann-La Roche Ag |
3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
|
|
EP3817741A4
(en)
|
2018-07-03 |
2022-07-06 |
The Board of Trustees of the University of Illinois |
ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
JP7448541B2
(ja)
*
|
2018-12-24 |
2024-03-12 |
インベンティスバイオ カンパニー リミテッド |
選択的エストロゲン受容体分解剤の新規な塩
|
|
AU2020223865A1
(en)
|
2019-02-22 |
2021-07-15 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
JP2022543832A
(ja)
|
2019-08-06 |
2022-10-14 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
変異体を治療するためのエストロゲン受容体調節剤
|
|
EP4045507A4
(en)
*
|
2019-11-04 |
2023-11-01 |
Recurium IP Holdings, LLC |
SALTS AND FORMS OF AN ESTROGEN RECEPTOR MODULATOR
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
AU2021205156B2
(en)
|
2020-01-10 |
2026-07-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
MX2022010425A
(es)
|
2020-03-06 |
2022-09-07 |
Olema Pharmaceuticals Inc |
Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
|
|
US20210330653A1
(en)
|
2020-04-24 |
2021-10-28 |
Astrazeneca Ab |
Dosage Regimen for the Treatment of Cancer
|
|
PE20221838A1
(es)
|
2020-04-24 |
2022-11-29 |
Astrazeneca Ab |
Formulaciones farmaceuticas
|
|
EP4164653A4
(en)
|
2020-06-15 |
2024-06-19 |
G1 Therapeutics, Inc. |
MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
BR112023002161A2
(pt)
*
|
2020-08-05 |
2023-04-04 |
Aizant Drug Res Solutions Private Limited |
Formas sólidas de dosagem de palbociclibe
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
EP4247977A2
(en)
|
2020-11-23 |
2023-09-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
EP4267578A4
(en)
|
2020-12-23 |
2024-11-20 |
Recurium IP Holdings, LLC |
ESTROGEN RECEPTOR MODULATORS
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
BR112023024507A2
(pt)
|
2021-05-26 |
2024-02-15 |
C4 Therapeutics Inc |
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
|
|
AU2022290851A1
(en)
|
2021-06-08 |
2023-11-23 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
WO2023283329A1
(en)
*
|
2021-07-08 |
2023-01-12 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
CN117642405B
(zh)
|
2021-07-09 |
2026-05-12 |
江苏恒瑞医药股份有限公司 |
一种三环四氢异喹啉类衍生物的盐型
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
KR20250055538A
(ko)
|
2022-08-03 |
2025-04-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret 단백질을 조정하기 위한 화합물
|
|
KR20250117789A
(ko)
|
2022-11-04 |
2025-08-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret-ldd 단백질 분해제
|
|
JP2025540906A
(ja)
|
2022-11-04 |
2025-12-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｒｅｔ－ｌｄｄタンパク質阻害剤
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
CN122206684A
(zh)
|
2023-06-30 |
2026-06-12 |
默克专利有限公司 |
用于kras蛋白降解的异双功能化合物
|
|
WO2025085738A1
(en)
|
2023-10-18 |
2025-04-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2025189056A1
(en)
|
2024-03-08 |
2025-09-12 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
WO2026139448A1
(en)
|
2024-12-23 |
2026-07-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|